Use of antibodies to intercellular adhesion molecule-1 (ICAM-1) in the treatment of asthma
US5324510A · kind A · utility
22Cited by
4References
4Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Mar 18, 1993 |
| Grant date | Jun 28, 1994 |
| Priority date | — |
| Expiry date | Mar 18, 2013 |
Classification
- Technology area (CPC Y)Emerging Cross-Sectional Technologies
- CPC primaryY10S530/868
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention provides a method of reducing the severity of asthma. Specifically, the present invention discloses that anti-adhesion antibodies, such as anti-ICAM-1 or anti-CD18 family member antibodies, when administered to a mammal, are capable of decreasing the hyperresponsive reaction associated with an asthmatic response.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.